The development of a dengue virus vaccine is a major priority in efforts to control the diseases. Several researchers are currently using the Asian 1 and Asian 2 genotypes as vaccine candidates for dengue type 2 virus (DENV-2). However, in this study, we constructed a recombinant plasmid-based prM/E gene, from a DENV-2 Cosmopolitan genotype strain as a dengue DNA vaccine candidate. The protein expression of the recombinant plasmid in CHO cells was analyzed using an enzyme-linked immunosorbent assay, western blotting, and sucrose gradient sedimentation. After being used to immunize ddY mice three times at doses of 25 or 100 mg, the DNA vaccine induced humoral immune responses. There was no difference in the neutralizing antibody titer (focus reduction neutralization test 50z value) of mice immunized with 25 and 100 mg DNA vaccine doses. When challenged with 3 × 10 5 FFU DENV-2, immunized mice could raise anamnestic neutralizing antibody responses, which were observed at day 4 and day 8 post-challenge. Analysis of immunogenicity using BALB/c mice showed that their antibody neutralization titers were lower than those of ddY mice. In addition, the antibodies produced after immunization and challenge could also neutralize a DENV-2 Asian 2 genotype (New Guinea C) strain. Therefore, the DENV-2 Cosmopolitan genotype may be a DENV-2 vaccine candidate.
INTRODUCTION
Dengue infections are caused by dengue viruses (DENV) and are endemic in tropical and subtropical regions. DENV are primarily transmitted by mosquitoes of the genus Aedes, particularly Aedes aegypti (1). The incidence of dengue infection has increased 30-fold over the last 50 years. Approximately 50-100 million infections are now estimated to occur annually in over 100 endemic countries, and almost half of the world's population is at risk (2) . At present, there is no effective antiviral treatment for dengue infection. Vaccination is a preventative method that may prove successful, as it has with other infectious diseases (3) . Several dengue vaccine candidates are being developed using different approaches, such as live attenuated (4) (5) (6) (7) (8) , chimeric (8) (9) (10) , recombinant subunit (8, (11) (12) (13) (14) , and DNA vaccines (8, (15) (16) (17) (18) (19) .
The use of DNA vaccines has significant advantages in developing and large countries. The advantages of DNA vaccines are that they can remain stable in warm temperatures and they have lower manufacturing costs. Compared with live vaccines, DNA vaccines have a better level of security, because live attenuated viruses are more likely to change and regain their virulence (20) . Although the development of chimeric and recombinant viruses by genetic engineering is a promising approach, potential complications remain, and studies have shown that tetravalent vaccine formulations elicit immune responses due to viral interference (21) . Viral interference is a particularly important concern during dengue vaccine development. Certain studies have shown that DNA vaccines are an appropriate strategy for overcoming the problem of viral interference (16) .
At present, there are no licensed vaccines for DENV, but a number of candidate dengue vaccines have been developed and evaluated in various experimental models. The pre-membrane (prM) and envelope (E) proteins of DENV are used as the basis for vaccine development, because they can induce neutralizing antibodies (NAbs) in immunized humans and mice (15, 16, 22) . The leading recombinant, live attenuated vaccine candidate produced by the Sanofi group is currently under in clinical trials, and early results suggest that it has a low protective efficacy against DENV type 2 virus (DENV-2), despite its satisfactory immunogenicity. In addition to viral interference problems, differences in the circulating virus may cause failure of a DENV-2 vaccine (23). DENV-2 has been classified into six genotypes, Asian 1, Asian 2, American, American/Asian, Cosmopolitan, and Sylvatic. Previously, development of DENV-2 vaccine candidates has used strains belonging to the Asian 1, Asian 2, or American genotypes (9, 15, 24, 25) . There have been no studies using DENV-2 strains of the Cosmopolitan genotype as vaccine candidates, although the Cosmopolitan genotype is defined as a group of strains that has a nearly global distribution. Several epidemiological studies have reported a DENV-2 outbreak of this genotype in several areas, including Indonesia (26) (27) (28) (29) (30) .
In the present study, we constructed a DNA vaccine candidate based on the prM/E genes of a Cosmopolitan genotype strain, and showed that it could induce a humoral immune response. In addition, the antibodies produced after immunization with the DNA vaccine candidate could neutralize strains of other genotype in vitro i.e., the New Guinea C (NGC) strain of the Asian 2 genotype.
MATERIALS AND METHODS
Cells and viruses: Vero and Chinese hamster ovary (CHO) cells were grown in minimal essential medium (MEM) supplemented with 10z heat-inactivated fetal bovine serum, L-glutamine, penicillin, streptomycin, and Fungizone. The cultures were maintained at 379 C in an atmosphere of 5z CO 2 . This study used the DENV-2 strain, DS 18/09, which was obtained from the serum of a dengue hemorrhagic fever patient in 2009. Ethical approval was obtained from the Committee of Medical Research Ethics at the Faculty of Medicine, Universitas Indonesia (71/PT02.FK/ETIK/2009). The NGC strain was obtained from the National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia. Virus propagation was performed in Vero cells. Virus stocks were aliquoted and stored at -809 C, and viral titers were determined using focusforming assays in Vero cells.
Plasmid construction: Plasmid pUMD2 was prepared by inserting the prM/E gene from the DENV-2 DS18/09 strain into the pUMVC4a vector (Addgene, Cambridge, MA, USA). Viral RNA was isolated from sera of patients infected with DENV-2 and reverse transcribed into cDNA using random primers with SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). The prM/E gene of DENV-2 was subsequently amplified by PCR with KOD-Plus-NEO DNA polymerase (Toyobo, Osaka, Japan) ) using the forward and reverse primers, DV2_K-F (5′ -CGC-GAT-ATC-ACC-ATG-AAC-AGG-AGA-CGC-AGA-ACT-3′ ) and DV2_ R K-R (5′ -TGC-TCT-AGA-TTA-GGC-CTG-CAC-CAT-AAC-TCC-3′ ), respectively; the underlined nucleotides are the EcoRV and XbaI restriction sites used for cloning into the multi-cloning site of the pUMVC4a vector. DNA was prepared for immunization using a HiSpeed Plasmid Maxi kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. The DNA was re-suspended in elution buffer and diluted with 1× phosphate-buffered saline before injection.
In vitro expression analysis of constructs: The expression of DENV-2 virus E protein by pUMD2 was determined in CHO cells using Lipofectamine LTX with Plus Reagents (Invitrogen). In brief, CHO cells were grown in 24-well tissue culture plates to 70z-80z confluence. First, 1 mg of plasmid was incubated with 1 ml of Lipofectamine reagent in 100 ml of Opti-MEM medium (Gibco-BRL, Grand Island, NY, USA) for 5 min at room temperature. Next, 2 ml of Lipofectamine reagent was added, the mixture was incubated for 30 min, and DNA-liposome complexes were subsequently added to the cells. After incubation for 6 h at 379 C, 1 ml of complete growth medium was added to the cells, followed by incubation for another 24 h. To check the transfection efficiency, the cells were fixed with acetone and methanol (1:1) for 20 min at -209 C, stained with the 4G2 monoclonal antibody (E protein-specific, flavivirus cross-reactive), and incubated with the corresponding secondary antibody conjugated with fluorescein isothiocyanate. Samples were analyzed by fluorescence microscopy.
Extracellular particles were analyzed using an enzyme-linked immunosorbent assay (ELISA) and western blotting, as previously described (13) . In brief, the culture supernatants harvested from transfected cells were clarified and precipitated with 10z polyethylene glycol (PEG; molecular mass, approximately 6,000 Da). After centrifugation, the pellets were resuspended in 50 mM Tris/150 mM NaCl (pH 8.0) buffer and applied to a sucrose density gradient. The collected fractions were analyzed using an ELISA, to determine their E-antigen level. To study the in vitro protein expression kinetics, CHO cells were transfected using the same method. The cell culture supernatant and cells were collected at 24, 48, 72, and 96 h post transfection. The cell lysates were analyzed using an ELISA and western blotting.
Immunization and challenge of mice: Groups of six ddY mice (4-to 6-week-old males and females) were used to evaluate the efficacy of DNA immunization. The ddY mice were obtained from PT Biofarma (Bandung, Indonesia). The ddY mice were vaccinated three times at 3-week intervals using the pUMD2 DNA vaccine, by inoculation into both thighs with a needle-free jet injector (ShimaJET; Shimadzu, Kyoto, Japan). The pUMD2 plasmid doses were 25 or 100 mg. Two groups of mice were not vaccinated and were used as controls. Retro-orbital blood was collected 2 weeks after each vaccination. Three weeks after the final vaccination, the mice were challenged with an intraperitoneal dose of 3.5 × 10 5 FFU DENV-2 DS 18/09 to study the anamnestic response. Retro-orbital blood was collected 4, 8, and 21 days post-challenge.
BALB/c mice are the more common line used in the evaluation of vaccines, but research conducted by Imoto and Konishi (12) showed that ddY mice produce high levels of neutralizing antibodies after immunization with dengue DNA vaccines. In this study, we compared the immune responses of BALB/c and ddY mice, to support the results obtained with either strain alone. Using the same procedure described for ddY mice, a group of six 4-to 6-week-old male and female BALB/c mice was immunized, with 100 mg pUMD2, and another group of non-immunized BALB/c mice was used as control (20) . Ethical approval for this particular experiment was also obtained from the Committee of Medical Research Ethics at the Faculty of Medicine, Universitas Indonesia (34/PT02.FK/ETIK/2010).
Dengue-specific antibody measurement: Individual mouse serum samples were evaluated for the presence of DENV-2 antibodies using an ELISA. In brief, 100-fold dilutions of serum samples were added to plate wells coated with a 1:8 dilution of DENV-2 DS 18/09. After 
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Candidate DNA Vaccine from DENV-2 Cosmopolitan Genotype incubating and washing with washing buffer, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Kirkegaad & Perry Laboratory, Gaithersburg, MD, USA) was added, and the plates were incubated for 1 h. The plates were then washed five times with washing buffer and the color reaction was developed using the HRP substrate, 3,3′ ,5,5′ -tetramethylbenzidine. The reaction was stopped by the addition of 2 N H 2 SO 4 , before measuring the absorbance at 450 nm. Neutralization tests: The pooled sera from each group of mice were used to determine the presence of NAbs. The NAb titers were determined with Vero cells using the 50z focus reduction neutralization test (FRNT50). In brief, two-fold serial dilutions of test sera were mixed with DENV-2 DS 18/09 and incubated overnight on ice. The antibody-virus mixtures were then used to infect Vero cells. NAb titers were expressed as the maximum serum dilution that yielded a 50z reduction in focus number (the FRNT50 value).
Statistical analysis: Significant differences in the mean ELISA antibody titer were analyzed by Student's t-test. A probability levels (P) of less than 0.05 was considered significant.
RESULTS
Epitope sequence comparison among strains: A comparison of the predicted amino acid sequence of the DENV-2 DS18/09 E protein (GenBank accession number: KF857538) with that of the NGC or PUO 218 strains showed that they shared 97.3z and 96.4z similarity, respectively, and NGC shared 98.0z similarity with PUO 218. The NGC and PUO 218 strains were reported to be DENV-2 vaccine candidate by Konishi and Fujii (13) , and Sanofi group (4), respectively, and the latter is currently undergoing the clinical trials. Furthermore, the epitope containing sequences of the E proteins were analyzed, and 11 amino acid variations were observed between the DENV-2 DS 18/09 and NGC or PUO 218 strains, 7 of which were located within the actual epitope. The B-and T-cell epitopes were predicted based on bioinformatic analyses of the dengue type 1 virus Hawaii strain (28) (Fig. 1) .
Expression of the DENV-2 E protein in transfected CHO cells: A transient transfection experiment was performed to analyze the protein expression kinetics of plasmid pUMD2 in CHO cells. Observations were made at 24, 48, 72, and 96 h post transfection. The clarified supernatant and cell lysate were concentrated with PEG and analyzed by western blotting, followed by incubation with the anti-flavivirus E protein monoclonal antibody, 4G2 (Fig. 2A) . The E protein was detected at 24 h post transfection in the cell lysate and supernatant by an ELISA. In addition, western blot analysis of the cell lysate detected an E protein band, which was the same size as that in the positive control (DENV-2-infected supernatant). In contrast to the E protein in the cell lysate, transfection incubation time affected the level of E protein in the supernatant, which was higher at the end of the incubation period (96 h) compared to the early stage.
An immunofluorescence assay of CHO cells transfected with pUMD2 produced positive signals, showing that dengue virus prM-E protein was expressed in the cells and recognized by the antibodies used (data not shown). The sucrose gradient fractions of extracellular proteins produced after pUMD2 transfection were analyzed using an ELISA with the anti-E protein monoclonal antibody, 4G2. The E proteins were detected in the uppermost fractions (10z-20z sucrose) of the gradient (Fig. 2B) .
Immunogenicity of the pUMD2 DNA vaccine candidate in ddY mice: For the analysis of antibody responses, ddY mice were inoculated with 25 or 100 mg doses of pUMD2. According to the ELISA analysis, anti-dengue IgG responses were first detected 2 weeks after the initial immunization, and they increased after the second and third immunizations. After the third immunization, there was no significant difference between the mean IgG titers of ddY mice immunized with 25 mg (1.51 ± 0.26) or 100 mg (1.43 ± 0.28) doses of the plasmids (P ＞ 0.05). FRNTs were performed with sera samples from mice to assay the NAb titer induced by the DNA vaccine candidate. Using naä ƒve serum as the control, NAbs against pUMD2 were first detected 2 weeks after the second immunization, and NAb titers rapidly increased after the third immunization. In addition, there were no significant differences between the NAb titers of ddY mice immunized with the 25 or 100 mg doses of pUMD2. The FRNT50 values for Nab titers results were 1:320 to 1:1280 (Fig. 3) .
To evaluate the anamnestic response, the vaccinated groups of ddY mice were challenged 3 weeks after the final immunization with the DENV-2 DS 18/09 strain; a control group of non-immunized mice were challenged with the same virus. The groups of immunized mice had increased NAb titers at day 4 post-challenge. The NAb levels continued to increase until day 8 but declined after day 21. In general, there were no differences in NAb titer increases between the groups of mice immunized with plasmid doses of 25 and 100 mg. In contrast to the challenged mouse, there were no increases in NAb titer in the groups of mice immunized with the DNA vaccine that were not challenged with the DENV-2 DS 18/09 strain. There were also no reductions in NAb titer in the group of mice immunized with 25 mg doses of DNA vaccine but without the DENV-2 challenge. There were increases in the NAb titer when non-immunized mice were challenged with DENV-2, but their levels were lower than those of immunized mice at day 8 postchallenge (Fig. 4) .
Comparison of the immunogenicity of the pUMD2 DNA vaccine candidate in ddY and BALB/c mice: The immunogenicity of the DNA vaccine was also tested in BALB/c mice, which were immunized with pUMD2 dose of 100 mg. Fig. 5A shows that although IgG could be detected by an ELISA after the first immunization and NAbs were detected after the second immunization, 
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Candidate DNA Vaccine from DENV-2 Cosmopolitan Genotype the mean IgG titer of BALB/c mice was significantly lower than that of ddY mice (0.64 ± 0.22 and 1.43 ± 0.28, respectively; P ＜ 0.05) and the FRNT50 value for NAb titers produced by BALB/c mice (1:160) mice was lower than that of ddY mice (1:640). In contrast, the increase in NAb titer after challenge was greater in BALB/c mice compared to ddY mice. In ddY mice, the NAb titers after each immunization increased two-fold compared to NAb titers after the previous immunization, whereas NAb titers increased four-fold in BALB/c mice.
The capacity of NAbs against the Cosmopolitan genotype to cross-react with other DENV-2 genotypes was tested using the NGC strain (Fig. 5B) . The FRNT was performed using sera taken at 21 days postchallenge. The results showed that the NAbs of mice immunized with the pUMD2 DNA vaccine candidate could neutralize the DENV-2 NGC strain, for which the NAb titer was two-folds lower than that of DENV-2 18/09 strain. There were no differences between the NAb titers of the sera from ddY and BALB/c mice.
These results suggest that the DNA vaccine candidate could elicit immune responses against DENV-2 in mice.
DISCUSSION
In the present study, we constructed a DNA vaccine based on the prM/E genes of a DENV-2 Cosmopolitan genotype strain that was isolated in Jakarta during 2010. In a previous study, Konishi et al. developed a DNA vaccine based on the prM/E genes of the NGC strain (15) . A comparison of the amino acid sequences of the DS18/09 strain (Cosmopolitan genotype) with the PUO 218 (Asian 1 genotype) and NGC (Asian 2 genotype) strains detected differences in seven amino acids located in epitope sequences. We are uncertain how this may affect cross-protection against different genotypes. A previous study by Sjatha et al. showed that there were differences in the NAb titer for different genotypes (31) , and the present study detected a two-fold lower NAb titer after infection with the NGC strain. A phase IIb trial in Thai children elicited low levels of protection against DENV-2 infection, which may have been caused by different genotypes of the circulating virus (22) . In countries with a high dengue infection burden, we consider that a vaccine derived from local isolates would give better protection against circulating DENV. However, replicate experiments using isolates from different genotypes would be needed to give more insights into the different immunogenicity of DNA vaccines constructed from different genotypes. Unfortunately, we have not been able to carry out these experiments because of the limited isolates available in our laboratory. The protein expression level of the recombinant prM/E DENV-2 plasmid was analyzed using immunohistochemical assays (data not shown), as well as western blot and ELISA analyses, of the cell lysates and the culture supernatants of transfected cells. A transient transfection experiment was used to analyze the protein expression kinetics of the pUMD2 plasmid in CHO cells, with observations made at 24, 48, 72, and 96 h post-transfection. The E protein was detected at 24 h post-transfection in cell lysates and supernatants using an ELISA. In addition, western blot analysis of cell lysates detected an E protein band, which was the same size as that in the positive control (DENV-2-infected supernatant). In contrast to the E protein in the cell lysate, the transfection incubation time affected the level of E protein in the supernatant, which was higher at the end of the incubation period (96 h) compared with the early stage (Fig. 2) . The E protein level in the cell lysate was much higher than that in the supernatant, suggesting that the E protein derived from the pUMD2 expression plasmid was bound to the cell membrane. The present study showed that the DNA vaccine construct could induce NAbs in both ddY and BALB/c mice. In ddY mice, the ELISA showed an increase in the NAb titer after the second immunization, whereas the NAb titer was low after the second immunization based on the FRNT50 value but increased after the third immunization. At day 4 post-challenge, there was a twofold increase in the NAb titer in immunized mice but not in non-immunized mice. This minor increase in the immunized mice may have been due to the high antibody titer detected before the challenge.
